Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer

2 Aug 2019

Abstract excerpt

BRAF V600E and TERT promoter mutations, particularly their genetic duet, are well known to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of radioactive iodine (RAI) avidity in recurrent PTC is a major cause of treatment failure and hence poor clinical outcomes. This study investigated the role of mutation patterns in loss of RAI avidity in recurrent PTC. Methods: This was a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Radiation Dose and Imaging
Share to S100 Proteins and Annexins
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31375570
DOI: 10.2967/jnumed.119.227652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerPMID 31375570Read ↗

Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid CancerSemantic proximity Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

Efficacy of Radioiodine in Non-Distant Metastatic Papillary Thyroid Cancer with TERT-p Mutation at Initial DiagnosisSemantic proximity Read ↗

Mortality Risk Stratification by Combining <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid CancerSemantic proximity Read ↗

A six-genotype genetic prognostic model for papillary thyroid cancer.Semantic proximity Read ↗

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity Read ↗

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.Semantic proximity Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Semantic proximity Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancerSemantic proximity Read ↗

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in KoreaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.